Download presentation
Presentation is loading. Please wait.
1
Classification Criteria for axSpA
2
Differential Presentation of axSpA in Women vs Men
3
bDMARDs Approved by the European Medicines Agency (EMA) for axSpA
4
Pivotal RCTs for TNF Inhibitors in AS
5
C-axSpAnd: Phase 3 Study Evaluating Certolizumab Pegol vs Conventional Standard of Care Treatment in nr-axSpA
6
RAPID-axSpA: Certolizumab Pegol and Extra Spinal Manifestations
7
Use of TNF Inhibitors in Clinical Practice in Pregnant and Lactating Patients
8
Anti-TNF Treatment Prescription for WoCBA Patients With Chronic Inflammatory Diseases
9
Women With Chronic Rheumatic Diseases and Family Planning
10
Overarching Principles for Use of Antirheumatic Drugs Before and During Pregnancy
11
Abbreviations
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.